# Aurobindo Pharma (NSE: AUROPHARMA) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/AUROPHARMA · Pivot · prices to 22 Oct 2026

Aurobindo Pharma (NSE: AUROPHARMA) closed at ₹1,571.30 on 22 Oct 2026, down 0.01% on the day. With a market capitalisation of ₹92,688 Cr, it ranks 116th by market cap among the 4,183 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 26× trailing earnings, against a return on equity of 9.2% in FY26. Over the past year the share price has risen 40.0%. Its 52-week range is ₹1,080.10 (24 Oct 2025) to ₹1,740.00 (24 Sep 2026); the last close is 9.7% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹9,106 Cr (+16.9% year on year) and net profit ₹1,034 Cr (+25.7%), on a consolidated basis. Promoters held 51.88% of the company as of 30 Jun 2026; 13.75% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹1,571.30 |
| Market cap | ₹92,688 Cr |
| P/E (trailing) | 26 |
| ROE | 9.2% (FY26) |
| ROCE | 13.7% (FY26) |
| Debt to equity | 0.2 |
| 52-week high | ₹1,740.00 (24 Sep 2026) |
| 52-week low | ₹1,080.10 (24 Oct 2025) |
| 1-year return | +40.0% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹9,106 Cr | +16.9% | ₹1,034 Cr | +25.7% | ₹17.86 |
| Q4 FY26 | ₹8,752 Cr | +4.4% | ₹923 Cr | −1.3% | ₹15.86 |
| Q3 FY26 | ₹8,605 Cr | +9.0% | ₹909 Cr | +7.8% | ₹15.67 |
| Q2 FY26 | ₹8,237 Cr | +7.7% | ₹846 Cr | +3.7% | ₹14.61 |
| Q1 FY26 | ₹7,792 Cr | +3.0% | ₹822 Cr | −10.6% | ₹14.20 |
| Q4 FY25 | ₹8,381 Cr | +10.6% | ₹935 Cr | +1.6% | ₹15.56 |
| Q3 FY25 | ₹7,893 Cr | +8.6% | ₹844 Cr | −10.5% | ₹14.56 |
| Q2 FY25 | ₹7,646 Cr | +6.9% | ₹817 Cr | +8.7% | ₹14.00 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹31,724 Cr | ₹3,515 Cr |
| FY24 | ₹29,002 Cr | ₹3,186 Cr |
| FY23 | ₹24,855 Cr | ₹1,939 Cr |
| FY22 | ₹23,455 Cr | ₹2,678 Cr |
| FY21 | ₹24,775 Cr | ₹5,389 Cr |
| FY20 | ₹23,099 Cr | ₹2,845 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 51.88%
- Foreign institutions: 16.38%
- Domestic institutions: 25.10%
- Non-institutions: 6.64%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Laurus Labs](https://app.pivotnow.in/stock/LAURUSLABS) | ₹2,010.10 | ₹1,08,185 Cr | 121.7 | 8.0% |
| [Cipla](https://app.pivotnow.in/stock/CIPLA) | ₹1,312.60 | ₹1,07,516 Cr | 27.3 | 11.3% |
| [Dr. Reddy's Laboratories](https://app.pivotnow.in/stock/DRREDDY) | ₹1,236.20 | ₹1,03,416 Cr | 25 | 11.1% |
| [Mankind Pharma](https://app.pivotnow.in/stock/MANKIND) | ₹2,236.60 | ₹93,981 Cr | 48.4 | 11.7% |
| [Lupin](https://app.pivotnow.in/stock/LUPIN) | ₹1,929.60 | ₹87,880 Cr | 16.6 | 23.8% |
| [Max Healthcare Institute](https://app.pivotnow.in/stock/MAXHEALTH) | ₹804.80 | ₹79,514 Cr | 54.6 | 13.4% |

## Questions and answers

### What is the share price of Aurobindo Pharma today?

Aurobindo Pharma (NSE: AUROPHARMA) last closed at ₹1,571.30 on 22 Oct 2026. Its 52-week high is ₹1,740.00 and its 52-week low is ₹1,080.10.

### What is the market cap of Aurobindo Pharma?

Aurobindo Pharma's market capitalisation is ₹92,688 Cr (₹92,688 Cr) at the 22 Oct 2026 close, ranking 116th among the NSE companies Pivot tracks.

### What is the P/E ratio of Aurobindo Pharma?

Aurobindo Pharma trades at a trailing P/E of 26. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 48.4.

### What is the ROE and ROCE of Aurobindo Pharma?

Return on equity was 9.2% in FY26 and return on capital employed was 13.7% in FY26 (consolidated figures).

### Is Aurobindo Pharma a debt-free company?

No. Aurobindo Pharma's debt-to-equity ratio was 0.2 in FY26, with total debt of ₹803 Cr.

### What were Aurobindo Pharma's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Aurobindo Pharma reported revenue of ₹9,106 Cr, +16.9% year on year, and net profit of ₹1,034 Cr, +25.7% year on year.

### How has Aurobindo Pharma stock performed over the last year?

Aurobindo Pharma's share price has risen 40.0% over the past year, +2.5% over three months and −8.5% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Aurobindo Pharma?

As of 30 Jun 2026: promoters 51.88%, foreign institutions 16.38%, domestic institutions 25.10%, non-institutions 6.64%. 13.75% of promoter shares were pledged.

### Who are Aurobindo Pharma's competitors?

The listed Pharma & Healthcare companies closest to Aurobindo Pharma by market cap are Laurus Labs, Cipla, Dr. Reddy's Laboratories, Mankind Pharma, Lupin and Max Healthcare Institute.

### Is Aurobindo Pharma a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Aurobindo Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on AUROPHARMA against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.